- Clinical Trials
- April 2024
- 80 Pages
Global
From €1919EUR$2,000USD£1,653GBP
- Drug Pipelines
- July 2023
- 144 Pages
Global
From €10550EUR$10,995USD£9,086GBP
- Report
- January 2022
- 200 Pages
Global
From €7196EUR$7,500USD£6,198GBP
- Report
- June 2018
- 26 Pages
Global
From €9595EUR$10,000USD£8,264GBP
- Report
- June 2018
- 546 Pages
Global
From €21109EUR$22,000USD£18,181GBP
Zetia (ezetimibe) is a cholesterol-lowering medication used to treat high cholesterol and related conditions. It is part of a class of drugs known as cholesterol absorption inhibitors, which work by blocking the absorption of cholesterol from the intestine. Zetia is often prescribed in combination with statins, another type of cholesterol-lowering medication, to help reduce cholesterol levels. Zetia is also used to treat homozygous familial hypercholesterolemia, a rare genetic disorder that causes high cholesterol levels.
The Zetia market is a subset of the larger cardiovascular drugs market, which includes medications used to treat a variety of heart-related conditions. The cardiovascular drugs market is highly competitive, with many different companies offering a variety of medications.
Some companies in the Zetia market include Merck & Co., Inc., Pfizer, Inc., AstraZeneca, and Novartis AG. Show Less Read more